JP2004523535A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004523535A5 JP2004523535A5 JP2002561027A JP2002561027A JP2004523535A5 JP 2004523535 A5 JP2004523535 A5 JP 2004523535A5 JP 2002561027 A JP2002561027 A JP 2002561027A JP 2002561027 A JP2002561027 A JP 2002561027A JP 2004523535 A5 JP2004523535 A5 JP 2004523535A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- formula
- phenyl
- lower alkyl
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims 33
- 150000001875 compounds Chemical class 0.000 claims 31
- 125000000217 alkyl group Chemical group 0.000 claims 30
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 24
- 229910052739 hydrogen Inorganic materials 0.000 claims 22
- 239000001257 hydrogen Substances 0.000 claims 22
- 150000002431 hydrogen Chemical class 0.000 claims 13
- -1 nitro, benzyloxy, hydroxy Chemical group 0.000 claims 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 229910052736 halogen Inorganic materials 0.000 claims 9
- 150000002367 halogens Chemical class 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 208000002193 Pain Diseases 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 150000001721 carbon Chemical group 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 230000004770 neurodegeneration Effects 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 3
- 125000006002 1,1-difluoroethyl group Chemical group 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000035143 Bacterial infection Diseases 0.000 claims 2
- 208000000094 Chronic Pain Diseases 0.000 claims 2
- 208000023105 Huntington disease Diseases 0.000 claims 2
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 claims 2
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 208000005298 acute pain Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 230000001580 bacterial effect Effects 0.000 claims 2
- 208000022362 bacterial infectious disease Diseases 0.000 claims 2
- 208000029028 brain injury Diseases 0.000 claims 2
- 230000001684 chronic effect Effects 0.000 claims 2
- 230000006726 chronic neurodegeneration Effects 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000006239 protecting group Chemical group 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- AJFWRZUSIQFQKM-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-3-[(2-methylimidazol-1-yl)methyl]pyrazole Chemical compound CC1=NC=CN1CC1=NN(C=2C=C(Cl)C(Cl)=CC=2)C=C1 AJFWRZUSIQFQKM-UHFFFAOYSA-N 0.000 claims 1
- QUMOIQBLMRAOCX-UHFFFAOYSA-N 1-(3,4-dichlorophenyl)-4-imidazol-1-yl-3-methylpyrazole Chemical compound CC1=NN(C=2C=C(Cl)C(Cl)=CC=2)C=C1N1C=CN=C1 QUMOIQBLMRAOCX-UHFFFAOYSA-N 0.000 claims 1
- CCPINXHORPBKPE-UHFFFAOYSA-N 1-[[1-(4-chloro-3-methylphenyl)imidazol-4-yl]methyl]imidazol-2-amine Chemical compound C1=C(Cl)C(C)=CC(N2C=C(CN3C(=NC=C3)N)N=C2)=C1 CCPINXHORPBKPE-UHFFFAOYSA-N 0.000 claims 1
- WWLNOHNILZUXSW-UHFFFAOYSA-N 2-(3,4-dichlorophenyl)-4-[(2-methylimidazol-1-yl)methyl]pyridine Chemical compound CC1=NC=CN1CC1=CC=NC(C=2C=C(Cl)C(Cl)=CC=2)=C1 WWLNOHNILZUXSW-UHFFFAOYSA-N 0.000 claims 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 1
- SJBJJLMAIRXOTJ-UHFFFAOYSA-N 3-(3,4-dimethylphenyl)-5-[(2-methylimidazol-1-yl)methyl]pyridine Chemical compound CC1=NC=CN1CC1=CN=CC(C=2C=C(C)C(C)=CC=2)=C1 SJBJJLMAIRXOTJ-UHFFFAOYSA-N 0.000 claims 1
- HZFKNZVXVQVYMK-UHFFFAOYSA-N 3-(3-chloro-4-fluorophenyl)-5-[(2-methylimidazol-1-yl)methyl]pyridine Chemical compound CC1=NC=CN1CC1=CN=CC(C=2C=C(Cl)C(F)=CC=2)=C1 HZFKNZVXVQVYMK-UHFFFAOYSA-N 0.000 claims 1
- WPINCYFUGZDAJF-UHFFFAOYSA-N 3-(4-chloro-3-methylphenyl)-5-[(2-methylimidazol-1-yl)methyl]pyridine Chemical compound CC1=NC=CN1CC1=CN=CC(C=2C=C(C)C(Cl)=CC=2)=C1 WPINCYFUGZDAJF-UHFFFAOYSA-N 0.000 claims 1
- RASQRGFTCCTZCY-UHFFFAOYSA-N 3-(4-fluoro-3-methylphenyl)-5-[(2-methylimidazol-1-yl)methyl]pyridine Chemical compound CC1=NC=CN1CC1=CN=CC(C=2C=C(C)C(F)=CC=2)=C1 RASQRGFTCCTZCY-UHFFFAOYSA-N 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- NCTMEOZLIBUPHN-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)-2-[(2-methylimidazol-1-yl)methyl]pyridine Chemical compound CC1=NC=CN1CC1=CC(C=2C=C(Cl)C(Cl)=CC=2)=CC=N1 NCTMEOZLIBUPHN-UHFFFAOYSA-N 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 230000006931 brain damage Effects 0.000 claims 1
- 231100000874 brain damage Toxicity 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01101947 | 2001-01-29 | ||
| PCT/EP2002/000552 WO2002060877A1 (en) | 2001-01-29 | 2002-01-21 | Imidazole derivatives |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004523535A JP2004523535A (ja) | 2004-08-05 |
| JP2004523535A5 true JP2004523535A5 (enExample) | 2005-06-02 |
| JP4094956B2 JP4094956B2 (ja) | 2008-06-04 |
Family
ID=8176317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002561027A Expired - Fee Related JP4094956B2 (ja) | 2001-01-29 | 2002-01-21 | イミダゾール誘導体 |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US6610723B2 (enExample) |
| EP (1) | EP1358165B1 (enExample) |
| JP (1) | JP4094956B2 (enExample) |
| KR (1) | KR100619106B1 (enExample) |
| CN (2) | CN101798298B (enExample) |
| AR (1) | AR035422A1 (enExample) |
| AT (1) | ATE425147T1 (enExample) |
| BR (1) | BR0206758A (enExample) |
| CA (1) | CA2434813C (enExample) |
| CY (1) | CY1110265T1 (enExample) |
| DE (1) | DE60231477D1 (enExample) |
| DK (1) | DK1358165T3 (enExample) |
| ES (1) | ES2319967T3 (enExample) |
| GC (1) | GC0000318A (enExample) |
| GT (1) | GT200200013A (enExample) |
| JO (1) | JO2292B1 (enExample) |
| MX (1) | MXPA03006773A (enExample) |
| MY (1) | MY138334A (enExample) |
| PA (1) | PA8537801A1 (enExample) |
| PE (1) | PE20020917A1 (enExample) |
| PT (1) | PT1358165E (enExample) |
| WO (1) | WO2002060877A1 (enExample) |
| ZA (1) | ZA200305626B (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7030144B2 (en) * | 2002-05-02 | 2006-04-18 | Neurogen Corporation | Substituted imidazole derivatives: GABAA receptor ligands |
| US7223759B2 (en) | 2003-09-15 | 2007-05-29 | Anadys Pharmaceuticals, Inc. | Antibacterial 3,5-diaminopiperidine-substituted aromatic and heteroaromatic compounds |
| MXPA06014909A (es) * | 2004-06-18 | 2007-02-28 | Chiron Corp | Derivados de n-(1-(1-bencil -4-fenil-1h -imidazol -2-il)-2, 2-dimetilpropil) benzamida y compuestos relacionados como inhibidores de proteina de huso de cinesina (ksp) para el tratamiento del cancer. |
| ITRM20050094A1 (it) * | 2005-03-04 | 2006-09-05 | Univ Siena | Derivati del 1-(1,5-di(4-clorofenil)-2metil-1h-3-pirroli)metil)-4-metilpiperazina (bm 212), procedimento per la loro produzione e uso di essi come antitubercolari. |
| US7939556B2 (en) | 2005-10-14 | 2011-05-10 | Neurosearch A/S | Imidazole derivatives and their use for modulating the GABAA receptor complex |
| KR100694181B1 (ko) * | 2005-11-25 | 2007-03-12 | 연세대학교 산학협력단 | 근원세포 또는 근섬유로부터 신경세포 분화를 유도하는화합물, 이를 포함하는 약학적 조성물, 신경세포 분화를유도하는 방법 및 신경세포 분화를 유도하는 화합물을검색하는 스크리닝 방법 |
| RU2472788C9 (ru) * | 2007-05-23 | 2013-04-20 | Аллерган, Инк. | (бициклогетероарил)имидазолил)метилгетероарильные соединения как агонисты адренергических рецепторов |
| WO2010009327A1 (en) * | 2008-07-17 | 2010-01-21 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Compounds for the treatment of pathologies associated with aging and degenerative disorders |
| BRPI0916576A2 (pt) | 2008-08-04 | 2017-06-27 | Chdi Inc | pelo menos uma entidade química, composição farmacêutica, e, método para tratar uma condição ou distúrbio. |
| NZ601547A (en) | 2010-01-25 | 2014-04-30 | Chdi Foundation Inc | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| WO2011101457A1 (en) | 2010-02-18 | 2011-08-25 | B.R.A.I.N. Biotechnology Research And Information Network Ag | Chimeric surface active proteins |
| JP2013540145A (ja) * | 2010-10-21 | 2013-10-31 | ウニベルシテート デス ザールランデス | コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤 |
| SG2014012926A (en) | 2011-08-30 | 2014-06-27 | Chdi Foundation Inc | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| WO2013033068A1 (en) | 2011-08-30 | 2013-03-07 | Stephen Martin Courtney | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| JP6130383B2 (ja) | 2011-09-30 | 2017-05-17 | エンドゥ ファーマシューティカルズ，インコーポレイティド | ピリジン誘導体 |
| JP6105594B2 (ja) | 2011-09-30 | 2017-03-29 | エンドゥ ファーマシューティカルズ，インコーポレイティド | 癌処置用ｃｙｐ１７阻害剤としてのイミダゾール誘導体 |
| MX372995B (es) | 2014-07-17 | 2020-04-13 | Chdi Foundation Inc | Metodos y composiciones para el tratamiento de trastornos relacionados con vih. |
| PT3180315T (pt) | 2014-08-15 | 2020-05-27 | Janssen Pharmaceuticals Inc | Pirazoles |
| EP3180329B1 (en) * | 2014-08-15 | 2020-03-18 | Janssen Pharmaceuticals, Inc. | Triazoles as nr2b receptor inhibitors |
| DE102015011861B4 (de) | 2015-09-10 | 2018-03-01 | Rudolf Schindler | Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren |
| KR20180108822A (ko) | 2016-02-10 | 2018-10-04 | 얀센 파마슈티카 엔.브이. | Nr2b-선택적 nmda 조절제로서 치환된 1,2,3-트라이아졸 |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
| CR20200464A (es) | 2018-03-08 | 2021-04-14 | Incyte Corp | Compuestos diólicos de aminopirazina como inhibidores de pi3k-y |
| EP3774732A4 (en) | 2018-04-04 | 2022-02-09 | Janssen Pharmaceutica NV | PYRIDINE AND SUBSTITUTED PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| US20220324860A1 (en) | 2019-06-14 | 2022-10-13 | Janssen Pharmaceutica Nv | SUBSTITUTED PYRAZOLO[4,3-b]PYRIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS |
| AU2020291188A1 (en) | 2019-06-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Substituted heteroaromatic Pyrazolo-pyridines and their use as GluN2B receptor modulators |
| JP7667097B2 (ja) | 2019-06-14 | 2025-04-22 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用 |
| AU2020290772A1 (en) | 2019-06-14 | 2022-01-06 | Janssen Pharmaceutica Nv | Pyrazine carbamates and their use as GluN2B receptor modulators |
| EP3983413A1 (en) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica NV | Substituted pyrazolo-pyrazines and their use as glun2b receptor modulators |
| BR112021025132A2 (pt) | 2019-06-14 | 2022-01-25 | Janssen Pharmaceutica Nv | Carbamatos de piridina e seu uso como moduladores do receptor glun2b |
| SG11202112407PA (en) | 2019-06-14 | 2021-12-30 | Janssen Pharmaceutica Nv | Substituted pyrazolo-pyridine amides and their use as glun2b receptor modulators |
| CN115656401B (zh) * | 2022-11-09 | 2025-03-28 | 武汉海特生物创新医药研究有限公司 | 一种咪唑-4-甲酸乙酯纯度的hplc检测方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3627155A1 (de) | 1986-08-11 | 1988-02-18 | Schering Ag | Imidazol-derivate |
| CN1040107C (zh) * | 1993-01-02 | 1998-10-07 | 山道士有限公司 | 咪唑基甲基吡啶 |
| US5872136A (en) * | 1996-04-03 | 1999-02-16 | Merck & Co., Inc. | Arylheteroaryl inhibitors of farnesyl-protein transferase |
| US5998424A (en) * | 1997-06-19 | 1999-12-07 | Dupont Pharmaceuticals Company | Inhibitors of factor Xa with a neutral P1 specificity group |
| IT1300055B1 (it) | 1998-04-17 | 2000-04-05 | Boehringer Ingelheim Italia | Eterocicli con anello a 5 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmici |
| ATE257827T1 (de) | 1999-07-21 | 2004-01-15 | Hoffmann La Roche | Triazolderivate |
-
2001
- 2001-12-20 US US10/029,342 patent/US6610723B2/en not_active Expired - Lifetime
-
2002
- 2002-01-21 PT PT02714095T patent/PT1358165E/pt unknown
- 2002-01-21 EP EP02714095A patent/EP1358165B1/en not_active Expired - Lifetime
- 2002-01-21 WO PCT/EP2002/000552 patent/WO2002060877A1/en not_active Ceased
- 2002-01-21 AT AT02714095T patent/ATE425147T1/de active
- 2002-01-21 CN CN2010101215002A patent/CN101798298B/zh not_active Expired - Fee Related
- 2002-01-21 DE DE60231477T patent/DE60231477D1/de not_active Expired - Lifetime
- 2002-01-21 KR KR1020037009992A patent/KR100619106B1/ko not_active Expired - Fee Related
- 2002-01-21 MX MXPA03006773A patent/MXPA03006773A/es active IP Right Grant
- 2002-01-21 CA CA002434813A patent/CA2434813C/en not_active Expired - Fee Related
- 2002-01-21 DK DK02714095T patent/DK1358165T3/da active
- 2002-01-21 ES ES02714095T patent/ES2319967T3/es not_active Expired - Lifetime
- 2002-01-21 JP JP2002561027A patent/JP4094956B2/ja not_active Expired - Fee Related
- 2002-01-21 CN CN028042557A patent/CN1489580B/zh not_active Expired - Fee Related
- 2002-01-21 BR BR0206758-7A patent/BR0206758A/pt not_active IP Right Cessation
- 2002-01-24 PA PA20028537801A patent/PA8537801A1/es unknown
- 2002-01-24 PE PE2002000055A patent/PE20020917A1/es not_active Application Discontinuation
- 2002-01-25 AR ARP020100261A patent/AR035422A1/es not_active Application Discontinuation
- 2002-01-25 MY MYPI20020294A patent/MY138334A/en unknown
- 2002-01-28 GC GCP20021833 patent/GC0000318A/en active
- 2002-01-28 GT GT200200013A patent/GT200200013A/es unknown
- 2002-01-29 JO JO20029A patent/JO2292B1/en active
-
2003
- 2003-02-11 US US10/364,596 patent/US6683097B2/en not_active Expired - Lifetime
- 2003-02-13 US US10/365,995 patent/US6667335B2/en not_active Expired - Lifetime
- 2003-07-21 ZA ZA200305626A patent/ZA200305626B/en unknown
-
2009
- 2009-05-15 CY CY20091100522T patent/CY1110265T1/el unknown